Experimental infection and protection against ... - TI Pharma

204 Chapter 10
Figure 4. Number of parasites as measured by Q-PCR in controls (A) and immunised
volunteers (B). Parasitemia of control group (n=5) is shown as geometric mean and
95% confidence interval, immunised volunteers are plotted individually (n=6).
Parasitemia of volunteers with delayed patency is indicated by dashed lines.
ly, and reported adverse events compatible with clinical malaria. Fatigue and
headache were most commonly reported. An overview of all solicited possibly or
probably related adverse events is provided in Table 2.
For safety reasons related to a previously reported cardiac event [12], we
measured biochemical cardiovascular indicators assiduously throughout the
trial. Shortly after parasite detection by microscopy and initiation of antimalarial
treatment, d-dimer levels became elevated in all volunteers. The maximum
increase in d-dimer varied between 570 to 14,600 ng/ml, with a median peak of
1,600 ng/ml (n=7). Von Willebrand cleaving protease activity was decreased at